642.59
price down icon1.10%   -7.17
pre-market  시장 영업 전:  649.75   7.16   +1.11%
loading
전일 마감가:
$649.76
열려 있는:
$645
하루 거래량:
1.18M
Relative Volume:
1.60
시가총액:
$67.37B
수익:
$14.92B
순이익/손실:
$4.42B
주가수익비율:
15.66
EPS:
41.0422
순현금흐름:
$3.79B
1주 성능:
-9.86%
1개월 성능:
-14.02%
6개월 성능:
-14.99%
1년 성능:
+6.28%
1일 변동 폭
Value
$639.81
$650.32
1주일 범위
Value
$610.60
$717.88
52주 변동 폭
Value
$476.49
$821.11

리제네론 파마슈티컬스 Stock (REGN) Company Profile

Name
명칭
Regeneron Pharmaceuticals Inc
Name
전화
(914) 847-7000
Name
주소
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Name
직원
15,410
Name
트위터
@regeneron
Name
다음 수익 날짜
2026-04-29
Name
최신 SEC 제출 서류
Name
REGN's Discussions on Twitter

Compare REGN vs VRTX, ARGX, ALNY, RVMD

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
REGN icon
REGN
Regeneron Pharmaceuticals Inc
642.59 68.12B 14.92B 4.42B 3.79B 41.04
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
433.54 109.25B 12.34B 4.34B 3.71B 16.87
ARGX icon
ARGX
Argen X Se Adr
816.22 50.01B 4.16B 1.29B 734.26M 19.58
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
300.51 39.85B 4.29B 577.22M 641.34M 4.2086
RVMD icon
RVMD
Revolution Medicines Inc
153.73 31.96B 742.00K -1.37B -1.07B -7.0731

리제네론 파마슈티컬스 Stock (REGN) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2026-03-31 재개 Piper Sandler Overweight
2026-03-06 개시 Barclays Overweight
2026-01-07 업그레이드 BofA Securities Underperform → Buy
2025-12-03 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2025-11-24 개시 HSBC Securities Buy
2025-11-24 재개 Truist Buy
2025-11-13 개시 Scotiabank Sector Perform
2025-08-14 개시 Rothschild & Co Redburn Buy
2025-06-30 다운그레이드 Argus Buy → Hold
2025-05-30 다운그레이드 RBC Capital Mkts Outperform → Sector Perform
2025-05-30 다운그레이드 Wells Fargo Overweight → Equal Weight
2025-05-14 업그레이드 Citigroup Neutral → Buy
2025-04-22 재개 Cantor Fitzgerald Overweight
2025-02-05 업그레이드 Leerink Partners Market Perform → Outperform
2025-01-16 다운그레이드 UBS Buy → Neutral
2024-12-10 재개 BofA Securities Underperform
2024-11-15 개시 Wolfe Research Outperform
2024-11-14 개시 Citigroup Neutral
2024-09-24 다운그레이드 Leerink Partners Outperform → Market Perform
2024-03-12 개시 Bernstein Outperform
2024-01-12 업그레이드 RBC Capital Mkts Sector Perform → Outperform
2023-11-09 개시 Deutsche Bank Hold
2023-11-03 업그레이드 Raymond James Mkt Perform → Outperform
2023-08-21 업그레이드 Canaccord Genuity Hold → Buy
2023-08-21 재확인 Oppenheimer Perform
2023-06-28 다운그레이드 Canaccord Genuity Buy → Hold
2023-03-27 업그레이드 SVB Securities Market Perform → Outperform
2023-03-24 업그레이드 Jefferies Hold → Buy
2023-03-23 업그레이드 Raymond James Underperform → Mkt Perform
2023-01-30 업그레이드 Cowen Market Perform → Outperform
2023-01-20 업그레이드 JP Morgan Neutral → Overweight
2022-10-26 다운그레이드 Raymond James Mkt Perform → Underperform
2022-10-17 다운그레이드 Evercore ISI Outperform → In-line
2022-09-09 업그레이드 Jefferies Underperform → Hold
2022-09-09 업그레이드 Morgan Stanley Equal-Weight → Overweight
2022-07-25 다운그레이드 SVB Leerink Outperform → Mkt Perform
2022-07-13 개시 Cantor Fitzgerald Neutral
2022-06-06 개시 Jefferies Underperform
2022-05-23 개시 SVB Leerink Outperform
2022-01-05 다운그레이드 BofA Securities Neutral → Underperform
2022-01-03 업그레이드 Bernstein Mkt Perform → Outperform
2021-12-15 다운그레이드 Bernstein Outperform → Mkt Perform
2021-12-09 재개 Wells Fargo Overweight
2021-12-07 재개 Cowen Market Perform
2021-12-06 개시 Goldman Buy
2021-11-19 재개 BMO Capital Markets Outperform
2021-11-05 다운그레이드 The Benchmark Company Buy → Hold
2021-06-29 개시 H.C. Wainwright Buy
2021-01-25 업그레이드 BMO Capital Markets Market Perform → Outperform
2021-01-13 업그레이드 The Benchmark Company Hold → Buy
2021-01-08 업그레이드 Citigroup Neutral → Buy
2020-10-05 업그레이드 Cantor Fitzgerald Neutral → Overweight
2020-08-20 다운그레이드 The Benchmark Company Buy → Hold
2020-07-09 업그레이드 SunTrust Hold → Buy
2020-05-26 업그레이드 Wells Fargo Equal Weight → Overweight
2020-04-28 다운그레이드 Citigroup Buy → Neutral
2020-04-17 업그레이드 The Benchmark Company Hold → Buy
2020-04-08 개시 The Benchmark Company Hold
2020-03-31 개시 Wolfe Research Peer Perform
2020-02-27 개시 Barclays Overweight
2020-02-26 업그레이드 Canaccord Genuity Hold → Buy
2020-02-26 다운그레이드 Robert W. Baird Outperform → Neutral
2020-02-25 업그레이드 Jefferies Hold → Buy
2020-02-11 업그레이드 Argus Hold → Buy
2019-12-24 개시 Raymond James Mkt Perform
2019-12-16 다운그레이드 Evercore ISI Outperform → In-line
2019-12-13 업그레이드 Credit Suisse Neutral → Outperform
2019-11-12 개시 SunTrust Hold
2019-11-07 업그레이드 Citigroup Neutral → Buy
2019-10-17 재개 BofA/Merrill Neutral
2019-09-23 업그레이드 Guggenheim Neutral → Buy
모두보기

리제네론 파마슈티컬스 주식(REGN)의 최신 뉴스

pulisher
May 21, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc.REGN - PR Newswire

May 21, 2026
pulisher
May 21, 2026

Regeneron reports positive trial results for amyloidosis treatment By Investing.com - Investing.com Canada

May 21, 2026
pulisher
May 21, 2026

Regeneron Pharmaceuticals Reports Encouraging LINKER-AL2 Trial Results for Lynozyfic® in Systemic AL Amyloidosis - Quiver Quantitative

May 21, 2026
pulisher
May 21, 2026

Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch

May 21, 2026
pulisher
May 21, 2026

Regeneron Pharmaceuticals, Inc. Cash Flow – BVL:REGNUS - TradingView

May 21, 2026
pulisher
May 21, 2026

Jim Cramer on Regeneron: “There Could Be Some More Downgrades” - Insider Monkey

May 21, 2026
pulisher
May 21, 2026

CytomX Therapeutics to Present at Upcoming June Investor Conferences - GlobeNewswire Inc.

May 21, 2026
pulisher
May 20, 2026

Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch

May 20, 2026
pulisher
May 20, 2026

Regeneron backed Parabilis Medicines seeks U.S. IPO - Seeking Alpha

May 20, 2026
pulisher
May 20, 2026

REGN Investor Alert: Levi & Korsinsky Investigates Regeneron Pharmaceuticals, Inc. (REGN) for Potential Securities Fraud - Business Wire

May 20, 2026
pulisher
May 20, 2026

After raising $800M, Parabilis seeks an IPO to pursue ‘undruggable’ targets - Yahoo Finance

May 20, 2026
pulisher
May 20, 2026

Tredje AP fonden Takes Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

May 20, 2026
pulisher
May 20, 2026

Resona Asset Management Co. Ltd. Has $24.71 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

May 20, 2026
pulisher
May 20, 2026

ProShare Advisors LLC Has $142.25 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

May 20, 2026
pulisher
May 20, 2026

Fideuram Intesa Sanpaolo Private Banking S.P.A. Takes Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

May 20, 2026
pulisher
May 20, 2026

Harvest Portfolios Group Inc. Has $63.10 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

May 20, 2026
pulisher
May 19, 2026

Scotiabank Maintains Regeneron Pharmaceuticals(REGN.US) With Hold Rating, Maintains Target Price $770 - Moomoo

May 19, 2026
pulisher
May 19, 2026

Research Alert: CFRA Lowers Rating On Shares Of Regeneron Pharmaceuticals, Inc To Hold From Buy - Moomoo

May 19, 2026
pulisher
May 19, 2026

symbol__ Stock Quote Price and Forecast - CNN

May 19, 2026
pulisher
May 19, 2026

Regeneron & Parabilis Sign Oncology Collaboration Worth Up to $2.2B - Yahoo Finance

May 19, 2026
pulisher
May 19, 2026

Can Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry? - Yahoo Finance Singapore

May 19, 2026
pulisher
May 19, 2026

A Look At Regeneron Pharmaceuticals (REGN) Valuation After Melanoma Trial Setback And Share Price Pullback - Yahoo Finance

May 19, 2026
pulisher
May 19, 2026

Regeneron Stock Tumbles 12% After Experimental Cancer Drug Misses Key Trial Goal - TIKR.com

May 19, 2026
pulisher
May 19, 2026

REGN Maintained by Canaccord Genuity -- Price Target Lowered to $875 - GuruFocus

May 19, 2026
pulisher
May 19, 2026

Canaccord Genuity Group Cuts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $875.00 - MarketBeat

May 19, 2026
pulisher
May 19, 2026

A Quick Look at Today's Ratings for Regeneron Pharmaceuticals(REGN.US), With a Forecast Between $770 to $968 - Moomoo

May 19, 2026
pulisher
May 19, 2026

REGN SHAREHOLDER INVESTIGATION: SueWallSt Investigates Regeneron Pharmaceuticals for Possible Securities Law Violations – Company AnnouncementFT.com - Financial Times

May 19, 2026
pulisher
May 19, 2026

Why Regeneron Pharmaceuticals (REGN) Is Down 11.7% After Key Melanoma Combo Trial Missed Its Goal - Yahoo Finance

May 19, 2026
pulisher
May 19, 2026

Canaccord lowers Regeneron stock price target on pipeline concerns By Investing.com - Investing.com Canada

May 19, 2026
pulisher
May 19, 2026

Regeneron teams up with Parabilis to advance novel antibody Helicon - The Pharma Letter

May 19, 2026
pulisher
May 19, 2026

UnitedHealth, Regeneron slip premarket; Dominion Energy, Delta Air Lines jump - Investing.com

May 19, 2026
pulisher
May 19, 2026

Regeneron signs $2.32bn deal with Parabilis for Helicon conjugates - Pharmaceutical Technology

May 19, 2026
pulisher
May 19, 2026

North Dakota State Investment Board Acquires Shares of 3,579 Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

May 19, 2026
pulisher
May 19, 2026

Regeneron Pharmaceuticals Inc stock (US7739031091): strategic Parabilis deal after REGN sell-off - AD HOC NEWS

May 19, 2026
pulisher
May 19, 2026

Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by Handelsbanken Fonder AB - MarketBeat

May 19, 2026
pulisher
May 19, 2026

Citigroup downgrades Regeneron Pharmaceuticals (REGN) - MSN

May 19, 2026
pulisher
May 19, 2026

Regeneron Melanoma Setback And New Collaboration Reshape Oncology Outlook - simplywall.st

May 19, 2026
pulisher
May 19, 2026

UnitedHealth, Regeneron Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Sahm

May 19, 2026
pulisher
May 19, 2026

Could Cash Machine Regeneron Pharmaceuticals Stock Be Your Next Buy? - Trefis

May 19, 2026
pulisher
May 19, 2026

Between Incyte and Regeneron Pharmaceuticals, Which Stock Looks Set to Break Out? - Trefis

May 19, 2026
pulisher
May 18, 2026

Wolfe Research lowers Regeneron stock price target to $860 on LAG-3 miss By Investing.com - Investing.com Australia

May 18, 2026
pulisher
May 18, 2026

Regeneron stock sinks after cancer trial miss prompts selloff - TechStock²

May 18, 2026
pulisher
May 18, 2026

Regeneron Pharma Update Signals New Market Watchpoint - Kalkine Media

May 18, 2026
pulisher
May 18, 2026

Regeneron Pharmaceuticals Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Regeneron Pharmaceuticals (REGN) - PR Newswire

May 18, 2026
pulisher
May 18, 2026

Regeneron (REGN) Faces Significant Decline, Drops Over 11% - GuruFocus

May 18, 2026
pulisher
May 18, 2026

Regeneron Partners With Parabilis To Reach Undruggable Targets - Citeline News & Insights

May 18, 2026
pulisher
May 18, 2026

Wolfe Research lowers Regeneron stock price target to $860 on LAG-3 miss - Investing.com Nigeria

May 18, 2026
pulisher
May 18, 2026

Regeneron Stock Sinks as Key Melanoma Drug Trial Fails to Beat Merck’s Keytruda - Barron's

May 18, 2026
pulisher
May 18, 2026

Investigation launched into Regeneron over misleading trial optimism and stock drop - Pluang

May 18, 2026
pulisher
May 18, 2026

U.S. Indexes Finished Mixed Monday As Cognizant Tech Solutions Led, Regeneron Pharmaceuticals Lagged - Barron's

May 18, 2026
pulisher
May 18, 2026

Wolfe Research Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $860 - Moomoo

May 18, 2026

리제네론 파마슈티컬스 (REGN) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$816.22
price up icon 1.49%
$300.51
price up icon 0.68%
$153.73
price up icon 2.26%
ONC ONC
$309.62
price up icon 0.29%
$433.54
price up icon 0.72%
자본화:     |  볼륨(24시간):